Artgen

Artgen is a Russian biotechnology company. It was founded in 2003. It is engaged in scientific research, development of innovative drugs and high-tech services in the field of regenerative medicine, medical genetics, gene therapy, bioinsurance and biopharmaceuticals. It independently promotes his own developments in the market.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Artgen balance sheet

Report period2020 2021 2022 2023 2024 2025
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Artgen cash flows

Report period2020 2021 2022 2023 2024 2025
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
OIBDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Artgen multipliers

Report period2020 2021 2022 2023 2024 2025
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/OIBDA
EV/EBITDA
EV/OIBDA

Artgen profitability

Report period2020 2021 2022 2023 2024 2025
ROA
ROE
ROS
EBITDA Margin
Operating margin
Artgen assets
Artgen cash flows
Artgen dividends
2.55%

Artgen dividend policy

The recommended amount of dividend payments is determined based on year-end financial results, economic situation, and industry position and may range from 40% to 60% of net profit.

Artgen shares

TickerNameTypeNominal valueISINPrice
ABIO:RMArtgenCommon shareRUB 0.1RU000A0JNAB6RUB 47

Artgen bonds

NameIssue sizePriceYield
ISKJ BO-01 (RUB)300,000 pcs.99.18%13.03%
Artgen BO-02 (RUB)300,000 pcs.108.1%15.09%

Artgen expected events

DateTypeNoteSource
10.06.2026 13:00
Meeting of shareholders
Shareholders will decide on dividends for 2025 year  disclosure.skrin.ru
19.06.2026 10:00
Dividends
The last day of purchase for receiving dividends RUB 1.2 per common share for 2025.  disclosure.skrin.ru
06.07.2026 10:00
Dividends
Deadline for payment of dividends RUB 1.2 per common share for 2025.  disclosure.skrin.ru
26.08.2026 10:00
Financial results
Financial statements for 6 months of 2026 in accordance with IFRSPictogram of artgen.ru  artgen.ru
Share capital structure of Artgen
Artgen news
14.05.2026
Betuvax, a company within the Arthgen Biotech group, has completed preclinical studies of a new drug Betufeld for the treatment of cat allergies. Studies on mice have confirmed the high specific activity and safety of the drug. Betuvax is currently finalizing the regulatory dossier. Within a year, the company plans to obtain approval from the Ministry of Hea...
Source: artgen.ru pictogram artgen.ru
Pictogram next
06.05.2026
Board of Directors of Artgen recommended that dividends be paid for 2025 in the amount of ₽1.2 per ordinary share. The last day of the purchase of securities to receive dividends is June 19, 2026. Dividend yield may amount to 2.17%.
Source: disclosure.skrin.ru
Pictogram next
27.04.2026
Artgen's IFRS net profit for 2025 was ₽107.68 million, a 2.2-fold decrease compared to ₽241.16 million in the previous year. Revenue increased by 13.3% to ₽1.7 billion, compared to ₽1.5 billion a year earlier.
Source: e-disclosure.ru pictogram e-disclosure.ru
Pictogram next
01.04.2026
Artgen's RAS net profit for 2025 amounted to ₽303.6 million, an increase of 14.4% compared to ₽265.5 million in the previous year. Revenue tripled to ₽361.4 million compared to ₽119.9 million a year earlier.
Source: e-disclosure.ru pictogram e-disclosure.ru
Pictogram next
All Artgen news
General information
Company nameArtgen
Tags#biotechnology, #pharmacy, #innovations of the russia
SectorHealth Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services
Business addressRF, g. Moskva
Mailing address117036, g. Moskva, prospekt 60-letiya Oktyabrya, d. 10A, etazh 3, pom. 24
CEOMasyuk Sergey Vladimirovich
Phone+7 (495) 646-80-76
Websiteartgen.ru
Information disclosuree-disclosure.ru